PNH Clinical Trial
Official title:
An Open-Label, Intrapatient, Dose-Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients With Paroxysmal Nocturnal Hemoglobinuria
This study evaluated the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of multiple intravenous (IV) doses of ALXN1210 administered to participants with PNH who have not previously been treated with complement inhibitor.
The data presented is up to the Primary Completion date of the study and is for the 24-week Primary Evaluation period. The study also includes an Extension Period of up to 5 years. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04725812 -
Complement Regulation to Undo Systemic Harm in Preeclampsia
|
Phase 2 | |
Recruiting |
NCT05539248 -
A Study on the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of CAN106 in Subjects With PNH
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03460301 -
Observational of PNH Type Cells in Korean Patients With Bone Marrow Failure Syndrome and Having Hemolytic PNH
|
N/A | |
Completed |
NCT01412047 -
Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study
|
N/A | |
Completed |
NCT02605993 -
Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
Phase 2 | |
Completed |
NCT05095168 -
Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) of CAN106 Administered Intravenously (IV) in Healthy Subjects
|
Phase 1 | |
Terminated |
NCT04702568 -
A Long Term Safety Study of BCX9930 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
Phase 2 | |
Completed |
NCT05337683 -
A Retrospective Chart Review Study to Evaluate the Impact of Eculizumab in Korean PNH Patients
|
||
Active, not recruiting |
NCT03531255 -
Pegcetacoplan Long Term Safety and Efficacy Extension Study
|
Phase 3 | |
Not yet recruiting |
NCT06449001 -
Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis
|
Phase 3 | |
Completed |
NCT03593200 -
A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH
|
Phase 2 | |
Completed |
NCT05884060 -
Retrospective Chart Review Screening Algorithm to Assess the Prevalence of PNH-clones
|
||
Available |
NCT05982938 -
Danicopan Early Access Program
|